Natural History of Noncirrhotic Portal Hypertension
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
A observational or N/A phase clinical study on Congenital Hepatic Fibrosis and Cystic Fibrosis, this trial is actively recruiting participants. The trial is conducted by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and has accumulated 44 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Study Description(click to expand)Study Description: Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion in the study. Objectives: Primary Objective: 1\. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and enhance transplant decision. Secondary Objectives: 1. Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting. 2. Identification of the genetic modifiers of NCPH. 3. Evaluation of hepatic transcriptome in absence and presence of NCPH. 4. Characterization of microbiome signatures in NCPH. Endpoints: Primary Endpoints: 1. Establish surveillance methods and guidelines for evaluation of NCPH. 2. Develop an understanding of the biological mechanisms of the progression of NCPH. 3. Identification of novel biomarkers correlating with NCPH progression. Secondary Endpoints: 1. Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity. 2. Establishment of positive or negative correlation between...
Study Description:
Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their
underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion
in the study.
Objectives:
Primary Objective:
1\. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our
findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and
enhance transplant decision.
Secondary Objectives:
1. Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting. 2. Identification of the genetic modifiers of NCPH. 3. Evaluation of hepatic transcriptome in absence and presence of NCPH. 4. Characterization of microbiome signatures in NCPH.
Endpoints:
Primary Endpoints:
1. Establish surveillance methods and guidelines for evaluation of NCPH. 2. Develop an understanding of the biological mechanisms of the progression of NCPH. 3. Identification of novel biomarkers correlating with NCPH progression.
Secondary Endpoints:
1. Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity. 2. Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype. 3. Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis. 4. Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species.
Status Flow
Change History
44 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
-
Feb 2026 — May 2026 [monthly]
Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Recruiting
▶ Show 39 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
-
Jun 2025 — Aug 2025 [monthly]
Recruiting
-
May 2025 — Jun 2025 [monthly]
Recruiting
-
Apr 2025 — May 2025 [monthly]
Recruiting
-
Jan 2025 — Apr 2025 [monthly]
Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Mar 2024 — Jul 2024 [monthly]
Recruiting
-
Sep 2023 — Mar 2024 [monthly]
Recruiting
-
Jun 2023 — Sep 2023 [monthly]
Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Recruiting
-
Sep 2022 — Mar 2023 [monthly]
Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting
-
Apr 2022 — May 2022 [monthly]
Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Recruiting
-
Nov 2021 — Jan 2022 [monthly]
Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
May 2020 — Nov 2020 [monthly]
Recruiting
-
Dec 2019 — May 2020 [monthly]
Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting
-
Nov 2018 — Nov 2019 [monthly]
Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Recruiting NA
-
May 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH. Objectives: \- To learn more about how NCPH develops over time. Eligibility: \- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse. Design: * Participants will have 2 screening visits. * Visit 1: to see if they have or may develop NCPH. * Medical history * Physical exam * Urine and stool studies * Abdominal ultrasound * Fibroscan. Sound waves measure liver stiffness. \<TAB\>- Visit 2: * Blood tests * Abdominal MRI * Echocardiogram * Questionnaire * Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein. * They may have a liver biopsy. * All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly. * Participants with NCPH will also have: * Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach. * At least every 2 years: Esophagogastroduodenoscopy. * At least every 4 years: testing including HVPG measurements and liver biopsy. * Participants without NCPH will also have: * Liver biopsy and HVPG measurements to see if they have NCPH. * Every 2 years: abdominal MRI and stool studies. * The study will last indefinitely.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .